Gute Zahlen von Maxim Pahrma - 500 Beiträge pro Seite

[gony]

Maxim Pharmaceuticals, Inc. (Nasdaq: MAXM) hat heute die Geschäftszahlen für das am 31. März 2001 endende zweite Quartal veröffentlicht. Danach betrug der Nettoverlust im zweiten Quartal 2001 9,758,000 USD oder 42 cents pro Aktie. Im Vergleich dazu lag der Nettoverlust für den Vergleichszeitraum des Jahres 2000 bei 12,649,000 USD oder 77 cents pro Aktie. Der Umsatz aus Kollaborationen belief sich im zweiten Quratal 2001 auf 871,000 USD, im Vergleichszeitraum des Vorjahres lag er bei lediglich 148,000 USD.

Für die am 31. März 2001 endenden sechs Monate betrug der Nettoverlust 22,725,000 USD oder 98 cents pro Aktie, im Vergleichszeitraum des Vorjahres wurde noch ein Nettoverlust von 25,092,000 USD, entsprechend 1,80 USD pro Aktie, erwirtschaftet. Der Umsatz aus Kollaborationen der letzten sechs Monate belief sich auf 1,701,000 USD, verglichen mit 288,000 USD für die Vergleichsperiode des Vorjahres. Die Abnahme des Nettoverlustes für die Zeiträume des laufenden Jahres sind teilweise darauf zurück zuführen, das die Ergebnisse für die gleichen Zeiträume des Vorjahres angefallene Dividenden für Vorzugsaktien enthielten, die vor Beginn des Geschäftsjahres 2001 in allgemeine Aktien konvertiert wurden. Bargeld, Bargeld Äquivalente und Investments beliefen sich am 31. März 2001 auf 162 Mio. USD.

[TS80]

Hey Leute habt Ihr Meinungen zu Maxim bin
seit heute investiert und glaube an
den Turnaround. Scheint ja einiges seltsam
gelaufen zu sein in der Vergangenheit darin
sehe ich aber auch einen rießen Chance.

[luto9]

Maxim Pharmaceuticals Announces 2002 First Quarter Financial Results
2/6/02




> Business Editors and Health/Medical Writers
BIOWIRE2K

SAN DIEGO--(BW HealthWire)--Feb. 6, 2002--Maxim Pharmaceuticals, Inc. (Nasdaq NM: MAXM)(SSE: MAXM) today announced results for the quarter ended December 31, 2001, the first quarter of its 2002 fiscal year. The loss before cumulative effect of accounting change for the first quarter totaled $7,825,000, or $0.34 per share, compared to a loss before cumulative effect of accounting change of $12,967,000, or $0.56 per share, for the same period of the prior year.
The Company had cash, cash equivalents and investments totaling $137.8 million at December 31, 2001. Maxim used net cash of $8.1 million in its operations during the quarter ended December 31, 2001, compared to $13.2 million used in operations for the same period of the prior year.
"We continue to maintain a cash expenditure level that is well within our expectations, and we are pleased that a number of key milestones in the advancement of our therapeutic candidates were completed during the last quarter," said Dale A. Sander, Maxim`s Senior Vice President, Finance and Chief Financial Officer. "Among the recent milestones related to the Ceplene(TM) technology were the commencement of two important clinical trials -- a second Phase 3 clinical trial in advanced metastatic melanoma with liver metastases and a Phase 2 trial in nonresponder hepatitis C patients. Looking forward, we expect to expand the clinical evaluation of Ceplene to patients with non-viral chronic liver diseases such as alcoholic liver disease (ALD) and nonalcoholic steatohepatitis (NASH). We also expect to commence three pilot studies of topical histamine in radiation dermatitis, oral mucositis and apthous stomatitis."
Effective October 1, 2001, the beginning of fiscal 2002, the Company adopted the provisions of a newly required accounting standard, Statement of Financial Accounting Standard ("SFAS") No. 142, Goodwill and Other Intangible Assets. SFAS No. 142 requires that goodwill and intangible assets with indefinite useful lives no longer be amortized, but instead be tested for impairment at least annually. Under the provisions of SFAS No. 142, Maxim was required for the first time to compare the carrying value of its assets, including goodwill, to the fair value of the Company, with the fair value based on the market price of the Company`s common stock. Based on the market price of the Company`s common stock, these analyses suggested that the implied fair value of the goodwill was zero. As a result, a charge of $28.2 million was recorded during the quarter ended December 31, 2001 reflecting the cumulative effect of adopting the new accounting principle and the related write down of goodwill. "This adjustment to goodwill is a non-cash, financial reporting event triggered by the relationship between our market capitalization and the carrying value of our assets and has no relevance to current or future operating results," said Mr. Sander.
As a result of the write down in goodwill, the net loss applicable to common stock for the first quarter totaled $36,004,000, or $1.55 per share, compared to a net loss applicable to common stock of $12,967,000, or $0.56 per share, for the same period of the prior year.

Company Overview

Maxim Pharmaceuticals is a global biopharmaceutical company with a diverse pipeline of product candidates for life-threatening cancers and hepatitis. Maxim`s research and development programs are designed to provide hope to patients most in need by developing safe and effective product candidates that have the potential to extend survival while maintaining quality of life. Maxim has attracted an experienced international management group and a team of employees dedicated to commercializing life-enhancing product candidates. Joining this motivated team in its mission are world-leading scientific and clinical investigators and major pharmaceutical development partners.
Ceplene, based on the naturally occurring molecule histamine dihydrochloride, prevents the production and release of oxygen free radicals. Research suggests that treatment with Ceplene has the potential to protect critical immune cells and to prevent damage associated with oxygen free radicals. Ceplene is currently being tested in Phase 3 cancer clinical trials for advanced metastatic melanoma and acute myelogenous leukemia. Phase 2 trials of Ceplene are also underway for the treatment of hepatitis C and advanced renal cell carcinoma. More than 1,300 patients have participated in the Company`s completed and ongoing clinical trials. Maxim is also developing small-molecule inhibitors and activators of programmed cell death, also known as apoptosis, that may serve as drug candidates for cancer, cardiovascular disease and other degenerative diseases. Lastly, the Company`s MaxDerm(TM) technology is designed for the treatment of medical conditions for which topical therapy is appropriate such as oral mucositis, herpes, decubitus ulcers, shingles, burns and related conditions.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the efficacy and intended utilization of Ceplene, the apoptosis modulator technology and MaxDerm, and regarding the Company`s clinical trials. Such statements are only predictions and the Company`s actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger-scale clinical trials, the risk that the Company will not obtain approval to market its products, the risk that clinical trials may not commence when planned, the risks associated with the dependence upon collaborative partners, and the fact that the Company will likely need to raise additional funds in the future, and if the Company is unable to obtain the funds necessary to continue its operations, it may be required to delay, scale back or eliminate one or more or its product commercialization programs. These factors and others are more fully discussed in the Company`s periodic reports and other filings with the Securities and Exchange Commission.

Note: Ceplene(TM), MaxDerm(TM) and the Maxim logo are trademarks of the Company.
Editor`s Note: This release is also available on the Internet at http://www.maxim.com.